

# Miriam Toledo Soler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033405/publications.pdf>

Version: 2024-02-01

33  
papers

1,505  
citations

377584

21  
h-index

466096

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Food craving-like episodes during pregnancy are mediated by accumbal dopaminergic circuits. <i>Nature Metabolism</i> , 2022, 4, 424-434.	5.1	13
2	The animal cachexia score (ACASCO). <i>Animal Models and Experimental Medicine</i> , 2019, 2, 201-209.	1.3	9
3	Complement C3 and Autophagy Keep the $\hat{I}^2$ Cell Alive. <i>Cell Metabolism</i> , 2019, 29, 4-6.	7.2	45
4	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. <i>JCSM Rapid Communications</i> , 2018, 1, 1-15.	0.6	3
5	Autophagy Regulates the Liver Clock and Glucose Metabolism by Degrading CRY1. <i>Cell Metabolism</i> , 2018, 28, 268-281.e4.	7.2	124
6	System-wide Benefits of Intermeal Fasting by Autophagy. <i>Cell Metabolism</i> , 2017, 26, 856-871.e5.	7.2	104
7	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. <i>Frontiers in Physiology</i> , 2017, 8, 184.	1.3	17
8	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 48-59.	2.9	45
9	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type <sc>II</sc> receptor inhibition and $\hat{I}^2$ agonist. <i>International Journal of Cancer</i> , 2016, 138, 2021-2029.	2.3	55
10	Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 84-94.	2.9	38
11	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. <i>Oncotarget</i> , 2015, 6, 43202-43215.	0.8	78
12	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 315-320.	2.9	44
13	A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation-contraction coupling together with additional muscle alterations. <i>Muscle and Nerve</i> , 2014, 49, 233-248.	1.0	20
14	Cachexia: a problem of energetic inefficiency. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014, 5, 279-286.	2.9	72
15	Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. <i>PLoS ONE</i> , 2014, 9, e113931.	1.1	24
16	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2770-2778.	1.1	83
17	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. <i>Journal of Lipid Research</i> , 2013, 54, 3045-3051.	2.0	17
18	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. <i>Oncology Letters</i> , 2012, 3, 185-189.	0.8	31

#	ARTICLE	IF	CITATIONS
19	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 37-43.	2.9	115
20	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. <i>E-SPEN Journal</i> , 2012, 7, e135-e138.	0.5	3
21	Theophylline is able to partially revert cachexia in tumour-bearing rats. <i>Nutrition and Metabolism</i> , 2012, 9, 76.	1.3	18
22	l-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer. <i>Clinical Nutrition</i> , 2012, 31, 889-895.	2.3	37
23	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 731-735.	0.8	16
24	Nutraceutical inhibition of muscle proteolysis: A role of diallyl sulphide in the treatment of muscle wasting. <i>Clinical Nutrition</i> , 2011, 30, 33-37.	2.3	10
25	Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 57-62.	2.9	22
26	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 87-93.	2.9	138
27	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011, 2, 95-104.	2.9	72
28	Interleukin-15 Affects Differentiation and Apoptosis in Adipocytes: Implications in Obesity. <i>Lipids</i> , 2011, 46, 1033-1042.	0.7	25
29	Effects of formoterol on protein metabolism in myotubes during hyperthermia. <i>Muscle and Nerve</i> , 2011, 43, 268-273.	1.0	5
30	Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2011, 10, 275-280.	1.1	0
31	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. <i>Oncology Reports</i> , 2011, 25, 189-93.	1.2	33
32	Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia. <i>Clinical Nutrition</i> , 2010, 29, 733-737.	2.3	27
33	The role of cytokines in cancer cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2009, 3, 263-268.	0.5	162